Find the investors funding Health rounds
326,000+ VC, angel and family-office profiles — direct emails, check sizes and stage filters.
Former Mural Oncology CEO launches new cancer biotech with $225M in venture capital - The Business Journals
A new cancer biotech company has been launched by the former CEO of Mural Oncology. The company has secured $225 million in venture capital funding to advance its cancer research and development efforts.
Former Mural Oncology CEO launches new cancer biotech with $225M in venture capital The Business Journals
| Sep 14, 2026 | Tandem Health | $100.0M | Series B | United Kingdom |
| Sep 14, 2026 | Aware Health | $12.0M | Seed | Switzerland |
| Sep 14, 2026 | Elita | $1.9M | — | Australia |
| Sep 09, 2026 | Seattle Children's spinout | $116.0M | — | — |
You just read who funded Mural Oncology. The same database has the investors behind every other round — with verified emails, check sizes and the stages they actually write at.
Free account: 15 investor contact unlocks a month, no card required.